-
13:00
-13:07
Single-cell screening of PARP inhibitor-induced malignant epithelial programs identifies an immune-visible prognostic axis in high-grade serous ovarian cancer
-
13:07
-13:14
The study of malic enzyme 1 driving the progression of epithelial ovarian cancer and platinum resistance through metabolic reprogramming
-
13:14
-13:21
Characterization and clinical relevance of an epithelial-retained plastic malignant-cell state in ovarian clear cell carcinoma
-
13:21
-13:28
Neutrophil extracellular traps restrict T cell infiltration by degrading C-X-C motif chemokine ligand 11 in high grade serous ovarian cancer
-
13:28
-13:35
Targeting DLST lipoylation with pyridoxal triggers therapeutic cuproptosis in ovarian cancer
-
13:35
-13:42
Advances in CAF-targeting strategies: translational challenges and future perspectives for refractory peritoneal metastasis in ovarian cancer
-
13:42
-13:49
Plasma cell-free RNA reveals tumor-specific metabolic remodeling in gynecological malignancies with tissue-plasma transcriptional concordance validation
-
13:49
-13:56
A multi-omics and pharmacogenomic prioritization of a FANCD2/USP1-associated DNA repair program in ovarian cancer treatment response
-
13:56
-14:03
Distinct geospatial immune contextures of primary and relapsed ovarian clear cell carcinoma

